Skip to main content

Sensi

Sensi Magazine January 2019 - Boston Digital Edition

Dec 27, 2018 01:32PM ● By Amber Orvik

HELLO, NEW YEAR

The year before us, 2019, should for all intents and purposes be a landmark one for the Bay State. Once the recreational industry has finally begun yawning to life, several years after voters approved Question 4 in Massachusetts, the recreational market triggered over $2.6 million in the first seven days of collecting revenue legally. State regulators are now thinking weed could generate between $93 million and $172 million in the 2020 fiscal year. 

This is also as good a year as any to really begin or maintain monitoring the last squeaks from the dying planet Prohibition. Take the axiom pot-fearing suburbanites or property owners love to tout to stoke financial insecurity, without any data, that loosely posits: If a cannabis outlet were to come to their town—windfall of tax revenue be damned—at the very least, homeowners would suffer the most. 

And yet, a recent study published in Contemporary Economic Policy found that homes prices in Denver, Colorado, increased 7.7 percent on average for any home within a quarter mile of a new dispensary in that robust market, and 4.7 percent for those within a half mile of one. So much for that old fiscal-panic rhetorical workhorse of a cannabis foe. It’s not just homeowners. They also found in the original weed town, Amsterdam, that losing a cannabis coffeeshop causes a 3 percent decrease in Airbnb rental prices, so even homeowners making side money on tourism take a hit when legal weed does in a flourishing marketplace. 

Then there’s simple observable reality for anyone willing to pay attention. Back in December, three of the largest common drugstore pharmacies–CVS, Walmart, and Family Dollar–had to issue an emergency recall for baby ibuprofen because of “higher concentrations of ibuprofen than listed.” A whoopsie that could be “especially dangerous for infants and could cause nausea, vomiting, epigastric pain, or diarrhea” as per the manufacturer of such wonderful medicine, Tris Pharma out of Monmouth Junction, New Jersey. Or put another way, synthetic medicine from corporate pharmacology has too much of the synthetic medicine in there to work as synthetic medicine, and instead will be a synthetic recipe for pain and suffering. In babies. 

Then on the other end of the spectrum, you’ve got endless stories about how properly administered and produced cannabis treatments for childhood autism, epilepsy, and a range of other issues continue to surface as parents begin to go public with their experiences. I’m fond of the one involving Las Vegas internet-famous baby “Carter,” who, despite suffering from Lamellar Icthyosis–a rare skin disorder causing dark “scales” to form all over the body that corrective surgery couldn’t cure–has found a new lease on life thanks to cannabis cream. 

Here’s to 2019 bringing more miracles for the kids, goodies and social consumption and economic empowerment for the adults, and Big Fun for anyone leaning on the leaf for whatever reasons in the months ahead. 

Dan McCarthy // MANAGING EDITOR // SENSI BOSTON 

Click on the image below to read the JANUARY 2019 issue of Sensi Magazine — Boston Edition